Hypera (HYPE3) Q3 2024 earnings summary

Executive summary

• Net revenue in Q3 2024 was R$1,915.9 million, down 10.4% year-over-year, mainly due to the start of working capital optimization, despite an 11% increase in sell-out and normalization of demand for flu, respiratory, pain, and fever products.

• Free cash flow increased 23.2% year-over-year to R$551.8 million, reflecting lower investment in working capital and absence of prior year acquisition payments.

• Net income from continuing operations was R$370.1 million in Q3 2024, a 25.9% decrease year-over-year.

• Board approved R$185.4 million in Interest on Equity (R$0.29/share) and achieved a 10% increase in Dow Jones Sustainability Index score.

• Working capital optimization process began, impacting net revenue and income due to lower inventory levels at clients, but did not affect sell-out performance.

Financial highlights

• Gross profit for Q3 2024 was R$1,145.7 million, with a gross margin of 59.8%, 3.5 p.p. lower than Q3 2023.

• EBITDA from continuing operations was R$561.2 million in Q3 2024, with a margin of 29.3%, down 8.0 p.p. year-over-year.

• Marketing expenses increased 6%, selling expenses up 5% YoY, and G&A expenses rose 10% due to higher consultancy and IT costs.

• Net debt after hedge at the end of Q3 2024 was R$6,997.8 million, reduced from R$7,260.3 million in Q2 2024.

• Cash and equivalents increased to R$3,208.6 million at quarter-end.

Outlook and guidance

• Working capital optimization expected to be 50% complete by end of Q4 2024, with most adjustments finalized by early 2025 and fine-tuning through the year.

• Anticipated strong cash generation from Q1 2025, with revenue growth resuming from mid-2025 as inventory adjustments normalize.

• CapEx for 2025 projected to be slightly higher than 2024, then declining to maintenance levels.

• The company discontinued its 2024 financial guidance due to the working capital optimization process, which is expected to generate R$2.5 billion in cash by 2028 and R$7.5 billion over 10 years.

• October 2024 preliminary sell-out growth reached 13%, with year-to-date growth at 9%.